Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Debio-0123 by Debiopharm International for Solid Tumor: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Debio-0123 by Debiopharm International for Astrocytoma: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase II for Astrocytoma. According to GlobalData, Phase II...
Debio-0123 by Debiopharm International for Glioblastoma Multiforme (GBM): Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
Debio-0123 by Debiopharm International for Peritoneal Cancer: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase...
Debio-0123 by Debiopharm International for Epithelial Ovarian Cancer: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
Debio-0123 by Debiopharm International for Uterine Cancer: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Uterine Cancer. According to GlobalData, Phase...
Debio-0123 by Debiopharm International for Fallopian Tube Cancer: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
Debio-0123 by Debiopharm International for Endometrial Cancer: Likelihood of Approval
Debio-0123 is under clinical development by Debiopharm International and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...